Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 121, Issue 2, Pages 500-507Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI45130
Keywords
-
Categories
Funding
- NIH National Institute of Neurological Disorders and Stroke [38194]
- CHDI
- NIH [DK32520]
Ask authors/readers for more resources
Huntington disease is an autosomal dominant neurodegenerative disorder caused by a toxic expansion in the CAG repeat region of the huntingtin gene. Oligonucleotide approaches based on RNAi and antisense oligonucleotides provide promising new therapeutic strategies for direct intervention through reduced production of the causative mutant protein. Allele-specific and simultaneous mutant and wild-type allele-lowering strategies are being pursued with local delivery to the brain, each with relative merits. Delivery remains a key challenge for translational success, especially with chronic therapy. The potential of disease-modifying oligonucleotide approaches for Huntington disease will be revealed as they progress into clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available